About LITS

Founded: 2000
Employees: 4
CEO: Justin File
WebsiteView website: www.litestrategy.com

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Recent LITS News & Updates

New Risk • Dec 24

New minor risk - Insider selling

There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$946k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (452% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Significant insider selling over the past 3 months (US$946k sold). Market cap is less than US$100m (US$51.1m market cap).

Recent updates

No updates

Lite Strategy, Inc. Stock Price

LITS Share Price Performance

LITS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Lite Strategy, Inc. Key Details

About LITS

Recent LITS News & Updates

Will Lite Strategy (NASDAQ:LITS) Spend Its Cash Wisely?

New minor risk - Insider selling

Insider recently sold US$946k worth of stock

Recent updates

Lite Strategy, Inc. Competitors

Sangamo Therapeutics

iBio

Entera Bio

MediciNova